TNF and rheumatoid arthritis: This review analyses the cardiovascular effects of methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and TNF inhibitors (infliximab, etanercept, adalimumab, and certolizumab) in RA management, emphasizing their safety and risks in CVD.